New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - follitropin alfa 150 [iu] (rch, + 10% overage);  ; lutropin alfa, rch 75 [iu] (+ 23% overage) - powder for injection - 150 iu/75 iu - active: follitropin alfa 150 [iu] (rch, + 10% overage)   lutropin alfa, rch 75 [iu] (+ 23% overage) excipient: dibasic sodium phosphate dihydrate methionine monobasic sodium phosphate monohydrate phosphoric acid polysorbate 20 sodium hydroxide sucrose water for injection - pergoveris is indicated for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials, these patients were defined by an endogenous serum lh of less than 1.2 iu/l.

European Union - English - myHealthbox

finox biotech ag - follitropin alfa - solution for injection in pre-filled pen (injection). - 75 iu/0.125ml - anovulation - sex hormones and modulators of the genital systems - in adult women - anovulation (including polycystic ovarian disease, pcod) in women who have been unresponsive to treatment with clomiphene citrate. - stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (art) such as in vitro fertilisation (ivf), gamete intra-fallopian transfer (gift) and zygote intra-fallopian transfer (zift). - follitropin alfa in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials these patients were defined by an endogenous serum lh level < 1.2 iu/l. in adult men - follitropin alfa is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human chorionic gonadotrophin (hcg) therapy.

European Union - English - EMA (European Medicines Agency)

theramex ireland limited - follitropin alfa - anovulation - sex hormones and modulators of the genital system, - in adult womenanovulation (including polycystic ovarian syndrome) in women who have been unresponsive to treatment with clomifene citrate;stimulation of multifollicular development in women undergoing superovulation for assisted reproductive technologies (art) such as in vitro fertilisation (ivf), gamete intra-fallopian transfer and zygote intra-fallopian transfer;ovaleap in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials these patients were defined by an endogenous serum lh level < 1.2 iu/l.in adult menovaleap is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotropic hypogonadism with concomitant human chorionic gonadotropin (hcg) therapy.

European Union - English - EMA (European Medicines Agency)

merck europe b.v. - follitropin alfa - anovulation; reproductive techniques, assisted; infertility, female; hypogonadism - sex hormones and modulators of the genital system, - anovulation (including polycystic ovarian disease, pcod) in women who have been unresponsive to treatment with clomiphene citrate.stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (art) such as in-vitro fertilisation (ivf), gamete intra-fallopian transfer (gift) and zygote intra-fallopian transfer (zift).gonal-f in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials these patients were defined by an endogenous serum lh level

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - corifollitropin alfa 0.2 mg/ml;   - solution for injection - 100 mcg/0.5ml - active: corifollitropin alfa 0.2 mg/ml   excipient: hydrochloric acid methionine polysorbate 20 sodium citrate sodium hydroxide sucrose water for injection - controlled ovarian stimulation (cos) for the development of multiple follicles and pregnancy in women undergoing in-vitro fertilisation techniques.

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - corifollitropin alfa 0.3 mg/ml;   - solution for injection - 150 mcg/0.5ml - active: corifollitropin alfa 0.3 mg/ml   excipient: hydrochloric acid methionine polysorbate 20 sodium citrate sodium hydroxide sucrose water for injection - controlled ovarian stimulation (cos) for the development of multiple follicles and pregnancy in women undergoing in-vitro fertilisation techniques.

Canada - English - Health Canada

emd serono, a division of emd inc., canada - follitropin alfa; lutropin alfa - kit - 150unit; 75unit - follitropin alfa 150unit; lutropin alfa 75unit - gonadotropins and antigonadotropins

Canada - English - Health Canada

emd serono, a division of emd inc., canada - follitropin alfa; lutropin alfa - solution - 300unit; 150unit - follitropin alfa 300unit; lutropin alfa 150unit - gonadotropins and antigonadotropins

Canada - English - Health Canada

emd serono, a division of emd inc., canada - follitropin alfa; lutropin alfa - solution - 450unit; 225unit - follitropin alfa 450unit; lutropin alfa 225unit - gonadotropins and antigonadotropins

Canada - English - Health Canada

emd serono, a division of emd inc., canada - follitropin alfa; lutropin alfa - solution - 900unit; 450unit - follitropin alfa 900unit; lutropin alfa 450unit - gonadotropins and antigonadotropins